Addex Shareholders Approve All Resolutions at Annual General Meeting
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, June 1, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (“the Company”), announced today that its shareholders approved, with a large majority, all of the proposals of the board of directors in its 2023 Annual General Meeting (AGM). The votes represented 32.24% of the company's outstanding capital.
Addex shareholders approved the 2022 annual report, the 2022 annual financial statements, the appropriation of the results as well as the compensation report (the latter in a consultative vote). All motions regarding the compensation of the board of directors and the executive management were also approved. In addition, discharge was granted to the members of the board of directors and the executive management for their activities during the business year 2022.
Dr. Vincent Lawton was re-elected as member and chairman of the board of directors and member of the compensation committee; Dr. Raymond Hill was re-elected as member of the board of directors and member of the compensation committee; and Dr. Roger Mills, Mr. Tim Dyer, Mr. Jake Nunn and Dr. Isaac Manke were re-elected as members of the board of directors.
BDO SA were re-elected as the auditors for the 2023 business year and Robert P. Briner, attorney-at-law, was re-elected as the independent voting rights representative until the 2024 Annual General Meeting.
Addex shareholders also approved the amendments of the Articles of Association. They approved the creation of a capital band, the increase of the conditional share capital, the possibility to grant loans to members of the Board of Directors and the Executive Management and the non-renewal of the exemption from the duty to make an offer granted to Growth Equity Opportunities Fund IV LLC and New Leaf Biopharma Opportunities on March 16, 2018, but expired on March 2, 2023.
The detailed agenda can be found on Addex’s website at https://www.addextherapeutics.com/en/investors/general-meetings/
About Addex Therapeutics:
Addex Forward Looking Statements:
Driving Business with Microsoft Expertise and Integration
Secure and Reliable IoT Connectivity Between Private and Public Wireless Networks